Endocrine Pharmacology Practice Questions

Q: A 30-year-old woman has experienced the loss of her newborn. She is currently producing breast milk leading to discomfort and the risk of developing a breast abscess due to milk stasis and incomplete emptying. Which of the following drugs can be used to prevent this complication?

Cabergoline. ***Cabergoline*** - **Cabergoline** is a dopamine agonist that inhibits prolactin secretion, thereby suppressing lactation and preventing breast engorgement and its complications after childbirth. - It has a longer duration of action compared to bromocriptine, allowing for less frequent dosing and better patient compliance in lactation suppression. *Chlorpromazine* - **Chlorpromazine** is an antipsychotic medication primarily used to treat psychotic disorders; it doesn't suppress lactation. - While it can cause hyperprolactinemia as a side effect due to its antidopaminergic action, it is not used to manage lactation or its complications. *Metoclopramide* - **Metoclopramide** is a dopamine receptor antagonist that *increases* prolactin levels, and is sometimes used to *stimulate* lactation, not suppress it. - It enhances gastrointestinal motility and is primarily used as an antiemetic or for gastric emptying disorders. *Mifepristone* - **Mifepristone** is a progesterone receptor antagonist primarily used for medical abortion and induction of labor. - It is not indicated for the suppression of lactation or the prevention of breast engorgement.

Q: A 55-year-old female with a history of diabetes and hypertension is undergoing a hysterectomy. Which medication should be avoided due to its potential to cause hyperglycemia?

Dexamethasone. ***Correct: Dexamethasone*** - **Dexamethasone** is a potent **corticosteroid** that significantly increases blood glucose levels through enhanced hepatic gluconeogenesis and peripheral insulin resistance - Particularly problematic in patients with **pre-existing diabetes**, where perioperative use can exacerbate **hyperglycemia** - Increases risk of surgical complications and requires intensive perioperative glucose management - Should be avoided or used with extreme caution in diabetic patients undergoing surgery *Incorrect: Lidocaine* - **Lidocaine** is a local anesthetic that does not affect glucose metabolism - Used for regional anesthesia and pain management with minimal systemic metabolic effects - Safe to use in diabetic patients *Incorrect: Fentanyl* - **Fentanyl** is an opioid analgesic that acts on pain perception pathways - Does not directly cause **hyperglycemia** or affect glucose homeostasis - Main side effects involve respiratory depression and sedation, not metabolic disturbances *Incorrect: Midazolam* - **Midazolam** is a benzodiazepine used for sedation and anxiolysis - Acts by enhancing GABAergic neurotransmission in the CNS - Does not cause **hyperglycemia** or affect glucose metabolism - Safe to use in diabetic patients from a glycemic control perspective

Q: A patient with type II diabetes is prescribed a drug that enhances insulin sensitivity by activating AMP-activated protein kinase (AMPK). What is the primary effect of AMPK activation on lipid metabolism?

Inhibits fatty acid synthesis. ***Inhibits fatty acid synthesis*** - **AMPK activation** leads to the phosphorylation and **inactivation of acetyl-CoA carboxylase (ACC)**, a key enzyme in fatty acid synthesis. - By inhibiting ACC, AMPK reduces the production of **malonyl-CoA**, which is both a substrate for fatty acid synthesis and an inhibitor of CPT-1, an enzyme crucial for fatty acid oxidation. - This is the **primary and direct action** of AMPK on lipid metabolism. *Promotes fatty acid oxidation* - While AMPK activation does generally promote **fatty acid oxidation**, this is an **indirect effect** resulting from the inhibition of fatty acid synthesis. - The inhibition of ACC relieves the malonyl-CoA-mediated inhibition of CPT-1, allowing fatty acid oxidation to proceed. - This is a secondary consequence, not the primary effect. *Stimulates lipid synthesis* - AMPK is a metabolic sensor that is activated during low energy states, and its primary role is to **conserve ATP**. - Stimulating lipid synthesis would be an **anabolic process** that consumes ATP, which is contrary to the energy-conserving role of AMPK. *Increases fatty acid storage* - Increased fatty acid storage, often in the form of triglycerides, is generally associated with an **excess of energy intake** and an increase in lipid synthesis. - AMPK's actions, by inhibiting fatty acid synthesis and promoting oxidation, would tend to **decrease fatty acid storage**, not increase it.

Q: A 25-year-old woman presents with hyperthyroidism. Which of the following is the first-line thionamide drug that inhibits thyroid hormone synthesis by blocking thyroid peroxidase?

Methimazole. ***Methimazole*** - **Methimazole** is the **first-line thionamide** drug that inhibits thyroid hormone synthesis by blocking the enzyme **thyroid peroxidase**. - This action prevents the **oxidation of iodide** and its subsequent organification (incorporation into tyrosine residues on thyroglobulin), thereby reducing the formation of **T3** and **T4**. - It has a **longer half-life** than PTU, allowing for **once-daily dosing**, and has a **better safety profile** (lower risk of hepatotoxicity). - **Preferred for most patients** with hyperthyroidism except in **first trimester of pregnancy** and **thyroid storm**. *Levothyroxine (synthetic thyroid hormone)* - **Levothyroxine** is a synthetic form of **thyroxine (T4)**, used to *replace* thyroid hormones in patients with **hypothyroidism**. - It does not *inhibit* thyroid hormone synthesis; rather, it *supplements* it. *Propranolol (beta-blocker)* - **Propranolol** is a **beta-adrenergic blocker** that primarily alleviates the **symptoms of hyperthyroidism** (e.g., palpitations, tremor, anxiety) by blocking the action of **catecholamines**. - It does not directly inhibit the **synthesis of thyroid hormones** but can block the peripheral conversion of T4 to T3. *Propylthiouracil (PTU)* - Like methimazole, **PTU** is a **thionamide** that inhibits thyroid hormone synthesis by blocking **thyroid peroxidase**. - However, PTU is **not first-line** due to **shorter half-life** (requires multiple daily doses) and **higher risk of hepatotoxicity**. - **Preferred only in specific situations**: **first trimester of pregnancy** (methimazole is teratogenic) and **thyroid storm** (due to additional inhibition of peripheral T4→T3 conversion).

Q: Which antidiabetic drug primarily works by reducing hepatic glucose production through AMPK activation?

Metformin. ***Metformin*** - **Metformin** is a biguanide that primarily works by **decreasing hepatic glucose production** through activation of **AMP-activated protein kinase (AMPK)**, which inhibits gluconeogenesis. - It also **increases insulin sensitivity** in peripheral tissues like muscle and adipose tissue as a secondary benefit. - First-line agent for type 2 diabetes mellitus due to its efficacy, safety profile, and weight-neutral or weight-loss effects. *Sulfonylureas* - **Sulfonylureas** primarily stimulate **insulin secretion** from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) and closing ATP-sensitive potassium channels. - They do not reduce hepatic glucose production or significantly increase insulin sensitivity. - Examples: glibenclamide, glipizide, gliclazide. *DPP-4 inhibitors* - **DPP-4 inhibitors** (gliptins) work by preventing the breakdown of **incretin hormones** (GLP-1 and GIP), which enhance glucose-dependent insulin secretion and suppress glucagon secretion. - Their primary mechanism does not involve direct reduction of hepatic glucose production or peripheral insulin sensitization. - Examples: sitagliptin, vildagliptin, linagliptin. *Thiazolidinediones* - **Thiazolidinediones (TZDs)** primarily improve **insulin sensitivity** in peripheral tissues (muscle and adipose) and liver by activating **peroxisome proliferator-activated receptor gamma (PPAR-γ)**. - They reduce hepatic glucose output indirectly through improved insulin sensitivity, but their primary action is peripheral insulin sensitization, not direct suppression of hepatic gluconeogenesis like metformin. - Examples: pioglitazone (rosiglitazone withdrawn in many countries).

Q: Which outcome best evaluates the effect of a new antidiabetic medication on patient health?

Measured decrease in HbA1c levels. ***Measured decrease in HbA1c levels*** - **HbA1c** provides an average measure of blood glucose control over the past 2-3 months, directly reflecting the medication's effectiveness in managing **hyperglycemia** [1]. - A significant decrease in HbA1c levels indicates improved **long-term glycemic control**, reducing the risk of diabetes-related complications [4]. *Patient reports of improved well-being* - While important, **patient reports of well-being** are subjective and can be influenced by various factors beyond glycemic control, such as the **placebo effect** or concurrent lifestyle changes. - They do not offer a **quantitative, objective measure** of the medication's direct impact on controlling blood sugar. *Weight loss* - **Weight loss** can be a beneficial side effect of some antidiabetic medications, but it is not the primary measure of their effectiveness in controlling **hyperglycemia** [2], [3]. - Many effective antidiabetic medications do not cause weight loss, and some can even cause weight gain, yet they still improve **glycemic control** [3]. *Decreased frequency of urination* - **Decreased frequency of urination** can be a symptom improvement in some diabetic patients, particularly those with severe hyperglycemia causing **polyuria**. - However, it is a **symptomatic outcome** and not a direct, objective measure of the medication's effectiveness in maintaining stable blood glucose levels over time, unlike HbA1c.

Q: Which antidiabetic drug is most likely to cause hypoglycemia due to increased insulin secretion from the pancreas?

Glipizide. ***Glipizide*** - **Glipizide** belongs to the class of **sulfonylureas**, which work by stimulating pancreatic beta cells to release more insulin, regardless of blood glucose levels. - This **insulin secretagogue** action directly increases the circulating insulin, making **hypoglycemia** a common and significant side effect, especially when food intake is delayed or insufficient. *Metformin* - **Metformin** primarily reduces **hepatic glucose production** and improves insulin sensitivity in peripheral tissues, rather than directly stimulating insulin secretion. - It has a very low risk of causing **hypoglycemia** when used as monotherapy because its mechanism does not involve increasing insulin levels beyond physiological needs. *Pioglitazone* - **Pioglitazone** is a **thiazolidinedione** that improves insulin sensitivity in target tissues by activating **PPAR-gamma receptors**. - It does not directly stimulate insulin secretion from the pancreas, so the risk of **hypoglycemia** is minimal when used alone. *Acarbose* - **Acarbose** is an **alpha-glucosidase inhibitor** that delays the absorption of carbohydrates from the gastrointestinal tract. - It does not affect insulin secretion, therefore, it does not cause **hypoglycemia** when used as monotherapy.

Q: A patient receives a medication for osteoporosis that selectively binds to bone surfaces and inhibits osteoclast activity. Which drug is used?

Alendronate. ***Alendronate*** - **Alendronate** is a **bisphosphonate** that selectively binds to bone surfaces and inhibits **osteoclast** activity, thereby reducing bone resorption. - Its mechanism of action leads to increased bone mineral density and reduced fracture risk in patients with **osteoporosis**. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that acts as an estrogen agonist in bone, reducing bone resorption, but does not directly bind to bone surfaces or inhibit osteoclasts. - It also has estrogen antagonist effects in breast and uterine tissue, differentiating it from bisphosphonates. *Calcitonin* - **Calcitonin** is a hormone that directly inhibits **osteoclast** activity, but it does not bind to bone surfaces like bisphosphonates do. - Its primary clinical use in osteoporosis is often for pain relief associated with acute vertebral fractures, and its overall efficacy for fracture prevention is less robust than bisphosphonates. *Teriparatide* - **Teriparatide** is a recombinant form of **parathyroid hormone (PTH)** that, when given intermittently, stimulates **osteoblast** activity and promotes new bone formation. - This is an **anabolic agent**, making it distinct from antiresorptive drugs that inhibit osteoclasts.

Q: A patient with osteoporosis is prescribed a selective estrogen receptor modulator (SERM). Which drug fits this description?

Raloxifene. ***Raloxifene*** - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that acts as an estrogen agonist in bone, helping to reduce bone resorption and increase bone mineral density. - It is used for the prevention and treatment of **osteoporosis in postmenopausal women**, and as an antagonist in breast tissue, it also reduces the risk of invasive breast cancer. *Denosumab* - **Denosumab** is a **monoclonal antibody** that targets and binds to **RANKL**, preventing osteoclast formation, function, and survival, thus reducing bone resorption. - It is not a SERM but a **receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor**, used for osteoporosis treatment. *Alendronate* - **Alendronate** is a **bisphosphonate**, which works by inhibiting osteoclast activity and reducing bone turnover. - It is not a SERM; its mechanism of action involves **binding to hydroxyapatite** in bone and inhibiting enzymes important for osteoclast function. *Calcitonin* - **Calcitonin** is a naturally occurring hormone that **inhibits osteoclast activity** and reduces bone resorption, but its anti-osteoporotic effects are weaker than other agents. - It is available as a nasal spray or injection for osteoporosis, but it is **not a SERM**; it directly acts on calcitonin receptors on osteoclasts.

Question 1

A 30-year-old woman has experienced the loss of her newborn. She is currently producing breast milk leading to discomfort and the risk of developing a breast abscess due to milk stasis and incomplete emptying. Which of the following drugs can be used to prevent this complication?

Accepted Answer

Cabergoline

Answer

Chlorpromazine

Answer

Metoclopramide

Answer

Mifepristone

Question 2

A 55-year-old female with a history of diabetes and hypertension is undergoing a hysterectomy. Which medication should be avoided due to its potential to cause hyperglycemia?

Accepted Answer

Dexamethasone

Answer

Lidocaine

Answer

Fentanyl

Answer

Midazolam

Question 3

A patient with type II diabetes is prescribed a drug that enhances insulin sensitivity by activating AMP-activated protein kinase (AMPK). What is the primary effect of AMPK activation on lipid metabolism?

Accepted Answer

Inhibits fatty acid synthesis

Answer

Promotes fatty acid oxidation

Answer

Stimulates lipid synthesis

Answer

Increases fatty acid storage

Question 4

A 25-year-old woman presents with hyperthyroidism. Which of the following is the first-line thionamide drug that inhibits thyroid hormone synthesis by blocking thyroid peroxidase?

Accepted Answer

Methimazole

Answer

Levothyroxine (synthetic thyroid hormone)

Answer

Propranolol (beta-blocker)

Answer

Propylthiouracil (PTU)

Question 5

Which antidiabetic drug primarily works by reducing hepatic glucose production through AMPK activation?

Accepted Answer

Metformin

Answer

Sulfonylureas

Answer

DPP-4 inhibitors

Answer

Thiazolidinediones

Question 6

Which outcome best evaluates the effect of a new antidiabetic medication on patient health?

Accepted Answer

Measured decrease in HbA1c levels

Answer

Patient reports of improved well-being

Answer

Weight loss

Answer

Decreased frequency of urination

Question 7

Which antidiabetic drug is most likely to cause hypoglycemia due to increased insulin secretion from the pancreas?

Accepted Answer

Glipizide

Answer

Metformin

Answer

Pioglitazone

Answer

Acarbose

Question 8

A patient receives a medication for osteoporosis that selectively binds to bone surfaces and inhibits osteoclast activity. Which drug is used?

Accepted Answer

Alendronate

Answer

Raloxifene

Answer

Calcitonin

Answer

Teriparatide

Question 9

What is the role of AMP-activated protein kinase (AMPK) in metabolic regulation, and which therapeutic strategy targeting AMPK is most effective for the treatment of type 2 diabetes?

Accepted Answer

AMPK activation increases insulin sensitivity; therefore, metformin is an effective treatment.

Answer

AMPK activation promotes lipid oxidation; therefore, statins are not appropriate.

Answer

AMPK activation enhances glucose uptake; therefore, sulfonylureas targeting AMPK are preferred.

Answer

AMPK activation suppresses gluconeogenesis; therefore, DPP-4 inhibitors are the most effective AMPK activators.

Question 10

A patient with osteoporosis is prescribed a selective estrogen receptor modulator (SERM). Which drug fits this description?

Accepted Answer

Raloxifene

Answer

Denosumab

Answer

Alendronate

Answer

Calcitonin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?